|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions显示文摘AIM To quantify drug-drug-interactions(DDIs) encountered in patients prescribed hepatitis C virus(HCV) treatment, the interventions made, and the time spent in this process.METHODS As standard of care, a clinical pharmacist screened for DDIs in patients prescribed direct acting antiviral(DAA) HCV treatment between November 2013 and July 2015 at the University of Colorado Hepatology Clinic. HCV regimens prescribed included ledipasvir/sofosbuvir(LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir(OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF), and sofosbuvir/ribavirin (SOF/RBV). This retrospective analysis reviewed the work completed by the clinical pharmacist in order to measure the aims identified for the study. The number and type of DDIs identified were summarized with descriptive statistics.RESULTS Six hundred and sixty four patients(83.4% Caucasian, 57% male, average 56.7 years old) were identified; 369 for LDV/SOF, 48 for OBV/PTV/r + DSV, 114 for SIM/SOF, and 133 for SOF/RBV. Fifty-one point five per cent of patients were cirrhotic. Overall, 5217 medications were reviewed (7.86 medications per patient) and 781 interactions identified (1.18 interactions per patient). The number of interactions were fewest for SOF/RBV (0.17 interactions per patient) and highest for OBV/PTV/r + DSV (2.48 interactions per patient). LDV/SOF and SIM/SOF had similar number of interactions (1.28 and 1.48 interactions per patient, respectively). Gastric acid modifiers and vitamin/herbal supplements commonly caused interactions with LDV/SOF. Hypertensive agents, analgesics, and psychiatric medications frequently caused interactions with OBV/PTV/r + DSV and SIM/SOF. To manage these interactions, the pharmacists most often recommended discontinuing the medication (28.9%), increasing monitoring for toxicities (24.1%), or separating administration times (18.2%). The pharmacist chart review for each patient usually took approximately 30 min, with additional time for more complex patients. CONCLUSION DDIs are common with HCV medications and management can require medication adjustments and increased monitoring. An interdisciplinary team including a clinical pharmacist can optimize patient care. | Jacob A Langness Matthew Nguyen Amanda Wieland Gregory T Everson Jennifer J Kiser | 2017 | World Journal of Gastroenterology2017,23,9: | 5 |
| 2 | To surcharge or not to surcharge: An empirical investigation of ATM pricing 显示文摘 | Hannah T H Kiser E K Prager R A | 2003 | The Review of Economics and Statistics2003,85,4: | 1 |
| 3 | Spectroscopic investigation of Cr( Ⅲ ) -and Cr( VI ) -treated nanoscale zerovalent iron显示文摘 | Manning B A Kiser J R Kwon H | 2007 | Environ SciTechnot2007,41,2: | 1 |
| 4 | Ionization and dissociation processes in phosphorus thichloride anddiphosphorus tetrachloride 显示文摘 | Sandoval A A Moser H C Kiser R W | 1963 | The Journal of Physical Chemistry1963,67,1: | 1 |
| 5 | Biosorption of nanoparticles to heterotrophic wastewater biomass显示文摘 | Kiser M A Ryu H Jang H | 2010 | Water Research2010,44,14: | 1 |
| 6 | Titanium nanomateri- al removal and release from wastewater treatment plants 显示文摘 | Kiser M A Westerhoff P Benn T | 2009 | Environmental science & technology2009,43,17: | 1 |
| 7 | Biosorption of nanop-articles to heterotrophic wastewater biomass显示文摘 | Kiser M A Ryu H Jang H | 2010 | WaterRes2010,44,14: | 1 |
| 8 | Biosorption of nanoparticles to heterotrophic wastewater biomass显示文摘 | Kiser M A Ryu H Jang H | 2010 | water research2010,44,14: | 1 |
| 9 | The role of binder content on microstmcture and properties of a Cu-base active brazing filler metal for diamond and cBN显示文摘 | ELSENER H R KLOTZ U E KHALID F A PIAZZA D KISER M | 2005 | Advanced Engineering Materials2005,7,5: | 1 |
| 10 | Reduction and immobilization of chromium(Ⅵ)by iron(Ⅱ)-treated faujasite显示文摘 | Jon R Kiser Bruce A Manning | 2010 | Journal of Hazardous Materials2010,174,: | 1 |
| 11 | Spectroscopic investigation of Cr(Ⅲ)and Cr(Ⅵ)treated nanoscale zerovalent iron显示文摘 | Manning B A Kiser J R Kwon H | 2007 | Environ Sci Technol2007,41,: | 1 |
| 12 | Gold mineralization in high-grade metamorphic shear zones of the Renco Mine,Southern Zimbabwe 显示文摘 | Kisers A F M Kolb J Meyer F M | 1998 | Economic Geology1998,93,: | 1 |
| 13 | Spectroscopic investigation of Cr( III)- and Cr(VI)-treated nanoscale zerovalent iron 显示文摘 | Manning B A Kiser J R Kwon H | 2007 | Environmental Science & Technology2007,41,2: | 1 |
| 14 | Evaluation of ultra-high temperature ceramics foraeropropulsion use显示文摘 | Stanley R Levine Elizabeth J Opila Michael C Halbig James D Kiser Mrityunjay Singh Jonathan A Salem | 2002 | Journal of the European Ceramic Society2002,,14: | 1 |
| 15 | Titanium nanomaterial removal and release from wastewater treatment plants 显示文摘 | KISER M A WESTERHOFF P BENN T | 2009 | Environmental Science and Technology2009,43,17: | 1 |
| 16 | Titanium nanomaterial removal and release from wastewater treatment plants显示文摘 | Kiser M A Westerhoff P Benn T | | 0,,17: | 1 |
| 17 | An expectation confirmation perspective of medical tourism显示文摘 | Chou S Y Kiser A I T Rodriguez E L | 2012 | Journal of Service Science Research2012,4,2: | 1 |
| 18 | Thermoacoustic CT:Imaging Principles显示文摘 | R A KRUGER W L KISER K D MILLER | 2000 | Proc SPIE2000,3916,: | 1 |
| 19 | Reduction and immobilization of chromium(Ⅵ)by iron(Ⅱ)-treated faujasite显示文摘 | Kiser J R Manning B A | 2010 | Journal of Hazardous Materials2010,174,13: | 1 |
| 20 | Reduction and immobilization of chromi- um(VI)by iron( II ) treated faujasite显示文摘 | J R Kiser B A Manning | 2010 | Journal of Hazardous Materi- als2010,174,13: | 1 |